TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02768779

Intervention type: OTHER
Intervention: Hair analysis
Description: Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
Study: NCT01817023

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Description: SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
Study: NCT02282280

Intervention type: DRUG
Intervention: Prilocaine Chlorhydrate
Description: Use of prilocaine in spinal anesthesia
Study: NCT01588782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1: Abiraterone
Description: 1000 mg abiraterone acetate tablet administered orally on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Abiraterone/Ketoconazole
Description: 400 mg ketoconazole tablets administered orally on Days 11 to 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Abiraterone/Ketoconazole
Description: 1000 mg abiraterone acetate tablet administered orally on Day 14
Study: NCT05706363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps graft
Description: Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps graft
Description: Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
Study: NCT04639960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal
Description: Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twelve weeks of placebo treatment.
Study: NCT00762554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depodur
Description: Depodur 10mg given epidurally at end of cesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depodur
Description: Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
Study: NCT04155606

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: microsurgery; endovascular interventions
Description: microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
Study: NCT01714310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine
Description: Titration and open label treatment from baseline visit for 12 week study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisdexamfetamine
Description: Titration and open label treatment from baseline visit for 12 week study.

Intervention type: DRUG
Group type: OTHER
Intervention: lisdexamfetamine
Description: Titration and open label treatment from baseline visit for 12 week study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initiated at end of study week 4 and continued to study week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Initiated at end of study week 4 and continued to study week 12.
Study: NCT00789282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary approach
Description: Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
Study: NCT02613559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: Intravitreal Injection
Study: NCT00789282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial approach - for enhanced care group
Description: optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reflects current patterns of care
Description: Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice.
Study: NCT01339975

Intervention type: BIOLOGICAL
Intervention: Biological sample
Description: 2 blood samples of 10mL + one urine sample~* on pre-operative d-1/d, post-operative d1 and d5(+/-2),~* one month post-operative,~* at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises.
Study: NCT02613247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Description: Intra-articular injection of 6 mL Hylan G-F 20
Study: NCT02636218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% NaCl
Description: 500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
Study: NCT01186237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early urinary catheter removal
Description: All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
Study: NCT01110590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 + Vardenafil
Description: Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 + Vardenafil
Description: Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
Study: NCT01339975

Intervention type: BIOLOGICAL
Intervention: Biological sample
Description: 2 blood samples of 10mL + one urine sample~* before starting the therapy~* at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~* at the end of the study or at the date of disease progression.
Study: NCT01225445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 2.5 mg daily
Study: NCT01110590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 + Vardenafil
Description: Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
Study: NCT01406821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet-rich-plasma (PRP) injection
Description: Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound-guided dry needling
Description: Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
Study: NCT01043796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide treated nets and wall liners
Description: Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide treated nets alone
Description: Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
Study: NCT00748644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
Study: NCT01248026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buttermilk
Description: Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)
Study: NCT01110590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04176250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-7371
Description: Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
Study: NCT01248026

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Buttermilk
Description: Consumption of the 2 experimental periods~1. buttermilk (45 g/d)~2. placebo (45 g/d,)
Study: NCT00934206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
Study: NCT02983019

Intervention type: DRUG
Intervention: Kagocel
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study: NCT05429450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Three periocular injections of methotrexate at week 0, week 3 and week 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
Study: NCT03019276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
Study: NCT03580629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Live Donor Champion Program
Description: Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
Study: NCT02613559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: Intravitreal Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: Intravitreal Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: Intravitreal Injection
Study: NCT00908544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHI-patients
Description: Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHI-patients
Description: Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
Study: NCT01541085

Intervention type: DRUG
Intervention: Darunavir/Ritonavir (DRV/r)
Description: Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen

Intervention type: DRUG
Intervention: Efavirenz (EFV)
Description: Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
Study: NCT00618371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK-0518)
Description: Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
Study: NCT01036854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1025
Description: orally, 24 mg, daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EUR-1025
Description: orally, 8 mg, twice daily over 6 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EUR-1025
Description: orally, 8 mg, three times a day over 6 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1025
Description: orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
Study: NCT04159389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental visualization
Description: Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
Study: NCT01091194

Intervention type: OTHER
Group type: OTHER
Intervention: Interval-based aerobic exercise
Description: High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
Study: NCT04880486

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education
Description: Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervision upper limb weight training exercise with VR
Description: Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.
Study: NCT03596203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransCutaneous Magnetic Stimulator (TCMS)
Description: TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
Study: NCT00124748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Imatinib is packaged in bottles as 100mg and 400mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: Imatinib is packaged in bottles as 100mg and 400mg tablets
Study: NCT05079048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK retentive elements
Description: received implant-supported mandibular overdenture retained by PEEK retentive element and housings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEK retentive elements
Description: received implant-supported mandibular overdenture retained by PEEK retentive element and housings
Study: NCT04112303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: Tablets administered orally once daily
Study: NCT03218436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAP treatment
Description: Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
Study: NCT03056742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stempeucel(R)
Description: Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
Study: NCT04637737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anterioposterior Weight Shifting Training with Visual Biofeedback
Description: The training group received an additional anterioposterior weight shifting training with visual Biofeedback 5 times per week for 4weeks. AP training is made to instantly know your training status during training by measuring and processing the foot pressure in real time using the F-Scan (Tekscan) hardware system and Software Development Kit (SDK).~Before training, all patients are instructed to place both feet at shoulder width, place the inverted foot approximately 30 cm in front of the unaffected side foot, move the body forward with the chest straight in an upright position, and be instructed to put the weight on the affected side.~On the screen shown, measure the maximum weight distribution during the first 10 times and set the value added by 5% as the target value.~It is designed to induce the maximum weight shift through the archery game.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional therapy
Description: The control group received the usual gait training.
Study: NCT00612755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + ribavirin
Description: Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
Study: NCT04851054

Intervention type: PROCEDURE
Intervention: Surgery for colon cancer with intention to cure
Description: Surgery by open or laparoscopic approach
Study: NCT00740584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% SPL7013 Gel (VivaGel)
Description: A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
Study: NCT02682368

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care Ultrasound by Surgeons (POCUSS)
Description: POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care Ultrasound by Surgeons (POCUSS)
Description: POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiology report
Description: Radiologist report compared to the point of care ultrasound impression.

Intervention type: PROCEDURE
Intervention: Surgery-Intra-operative findings
Description: Intra-operative findings compared to the previously performed point of care ultrasound.
Study: NCT01818596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Study: NCT04402879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP)
Description: The intervention for this study is PP. Patients at participating sites allocated to the intervention arm of the study will be prompted by ward nurses and respiratory therapists to assume and maintain a prone position for varying durations, four times per day until the occurrence of a primary outcome event or hospital discharge.~The target duration (dose) of PP is \> 8 hours per day for up to 60 days, or until oxygen requirements are \< 2 L per minute or \< 2 L per minute above baseline home oxygen requirements.
Study: NCT01366482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotavance Drug-Eluting Balloon
Description: Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon
Description: Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon
Description: Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
Study: NCT04392843

Intervention type: OTHER
Group type: OTHER
Intervention: Fasting
Description: Subjects remain fasted prior to insulin-induced hypoglycemia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feeding
Description: Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.